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The knowledge of the renin angiotensin system (RAS) has expanded with the identification of enzymes and peptides 
downstream of Ang II (Angiotensin II), such as Ang-(1-7), 
Ang III, and others.1–23 Ang-(1-7) forming enzymes do not 
only prevent and counteract Ang II overactivity but also foster 
Ang-(1-7) formation eliciting potentially beneficial actions 
of the latter peptide.7,11,14,15,24,25 There are 3 known carboxy-
peptidases that form Ang-(1-7) by cleaving Ang II: ACE2 
(angiotensin-converting enzyme 2),1–5,15 PRCP (prolylcar-
boxypeptidase),19,20,26–28 and prolyloligopeptidase (POP/PEP/
PREP/PE).10,23,29–34 The biological importance of conversion of 
Ang II to Ang-(1-7) is 2-fold: by lowering Ang II, its poten-
tially detrimental actions may be prevented; in addition, Ang-
(1-7) is being formed and this peptide has tissue-protective 
actions that are generally opposite to the unwanted chronic 
effects of excessive Ang II. This highlights the importance of 
enzymes that cleave Ang II to form Ang-(1-7).
It is also known from the work of Yamamoto et al34 that 
Ang-(1-7) can be formed directly from Ang I. The authors 
showed that, combined ACE (angiotensin-converting en-
zyme)/Neprilysin inhibition decreased Ang-(1-7) formation 
from Ang I infusion suggesting a critical role of Neprilysin 
on the formation of Ang-(1-7) directly from Ang I.34 In this 
study, however, Ang II was not infused. The goal of our study 
is to examine the relative contribution of enzymes that form 
Ang-(1-7) directly from Ang II. Of those, ACE2, a homolog of 
ACE with carboxypeptidase activity that is able to cleave both 
Ang I and Ang II is the best studied.20,26,35 The enzyme embod-
ies a metalloprotease active site and is widely distributed but 
principally expressed in the kidney, the heart, the intestine, 
and the testis.36–38
Two other enzymes are known to form Ang-(1-7) directly 
from cleavage of Ang II: PRCP and POP.32–38 PRCP is a serine 
carboxyprotease that cleaves the C-terminal amino acid of var-
ious peptides like Ang II, where the penultimate amino acid 
is Proline.26 The enzyme’s activity is extremely pH dependent 
with an optimum in the acidic range and essentially no activity 
at the physiological pH of plasma.20,26,35 POP is a serine pro-
tease that is involved in the enzymatic degradation of several 
biologically active peptides such as Ang I and Ang II.36–38 Due 
to its molecular structure, POP hydrolyses peptide hormones 
and neuropeptides, excluding high molecular weight peptides 
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and proteins.36 POP cuts at the C-side of an internal proline and 
can cleave Ang I to form Ang-(1-7), and Ang II to form Ang-(1-
7).23,29,37 Ang II contains proline at the seventh amino acid posi-
tion and Phenylalanine (Phe) at the eighth position. Therefore, 
the action of POP at the C-terminal end results in the forma-
tion of Ang-(1-7) and a release of Phe. POP is an intracellular 
enzyme localized in the cytoplasm38,39 but a membrane-bound 
form isolated from bovine brain has also been reported.40 The 
function of POP has mainly been studied in brain tissue, as it 
could be linked to some neurodegenerative diseases,41 and in 
neutrophil inflammation.42,43 Enzymatic activity for POP has 
been detected in lymphocytes, thrombocytes, renal cortex, ep-
ithelial cells, fibroblasts, and testis.38 POP activity also was re-
ported in plasma, but a physiological role of circulatory POP 
has not been established.44,45 In this study, we examined forma-
tion of Ang-(1-7) following the administration of Ang II and 
the impact of POP deficiency on acute Ang II-induced hyper-
tension. In addition, we examined the relative contribution to 
Ang-(1-7) formation from Ang II by POP and ACE2 ex vivo in 
serum, kidney, and lung tissues.
Methods
Methods used will be made available from the corresponding author 
on reasonable request (see online-only Data Supplement).
Ang II Injection to Evaluate Ang-(1-7) Formation
Male WT mice (C57Bl/6 background) at 10 to 20 weeks of age were 
intraperitoneally injected with Ang II (0.2 µg/g body weight). In 
some studies, 5 minutes after the Ang II bolus blood was drawn by 
cardiac puncture under euthasol anesthesia (see section Results) and 
the mice were euthanized by induction of double pneumothorax. In 
other studies following intraperitoneal Ang II, injection blood was 
collected from the tail tip snapped at 5 and 30 minutes post-infusion 
(this is specified under results). The same injection protocol was used 
for POP−/− and ACE2−/−/PRCP−/− mice (males, 20–24 weeks old).
In all the samples, Ang-(1-7) was measured by ELISA (see online-
only Data Supplement). In addition, in selected samples, the levels 
of plasma Ang-(1-7) together with Ang II and Ang-(1-5) were meas-
ured by LC/MS-MS (Attoquant Diagnostics) because our ELISA and 
RIA do not distinguish isoforms of those peptides, namely Ang III 
and Ang-(2-7). A radioimmunoassay (Hypertension Core Lab, Wake 
Forest University School of Medicine) was also used in the same se-
lected samples. This RIA uses a C-terminal directed antibody and 
cross-reacts with Ang-(2–7), and Ang-(3–7) with little or no cross-re-
activity with Ang I.46
ZPP, a POP inhibitor was given IP together with Ang II at a dose 
(1 µg/g BW) calculated to give a circulatory ZPP concentration in 
the 10 µmol/L range. At this concentration, this inhibition is selective 
for POP whereas at higher concentration (>100 µmol/L) also inhibits 
PRCP.23,47 The dose of ZPP (1 µg/g BW) has shown in our preliminary 
studies a nearly complete inhibition of serum POP activity.
Blood Pressure Measurement After Ang II Injection
The effect of POP deficiency on systolic blood pressure after Ang 
II infusion was studied in male POP−/− and WT mice (C57Bl/6 ge-
netic background) at 20 to 24 weeks of age. Systolic blood pressure 
was measured noninvasively in anesthetized mice by determining 
tail blood volume with a volume-pressure recording sensor and an 
occlusion tail-cuff using a computerized system (CODA System, 
Kent Scientific, Torrington, CT) as previously described14–16 (see also 
online-only Data Supplement).
Statistical Analyses
For comparison of 2 independent groups, a 2-tailed t test was used 
for normally distributed data. For not normally distributed data, a 
Mann-Whitney U test was used. For comparison of >2 independent 
groups, 1-way ANOVA was employed followed by Tukey multiple 
comparisons test. The significance over time between groups was 
evaluated by GLM model (SPSS, version 23). Results are presented 
in mean±SE and a P<0.05 was considered statistically significant.
Results
In Vivo Formation of Ang-(1-7) in Plasma After 
Infusion of Ang II
To examine Ang-(1-7) formation from Ang II, Ang II was 
injected intraperitoneally to wild-type mice. After an Ang II 
bolus, blood was collected and plasma levels of Ang-(1-7) 5 
minutes later were taken as evidence of rapid formation of this 
peptide from infused Ang II.
In control animals (n=5) which did not receive an Ang 
II bolus, plasma Ang II levels measured by ELISA were 
low (8.8±1.8 fmol/mL), whereas in Ang II-infused animals 
(n=6) Ang II levels at 5 minutes were about 100-fold higher: 
(968±213 fmol/mL). The infusion of Ang II resulted in mark-
edly elevated plasma Ang-(1-7) levels (1268±439 fmol/mL), 
measured by ELISA. To confirm the extremely high levels 
of plasma Ang-(1-7) after Ang II infusion, additional mea-
surements of Ang-(1-7) were performed by RIA in the same 
plasma samples from Ang II-infused mice. The values of 
Ang-(1-7) obtained by RIA were also high and not signifi-
cantly different from those obtained by ELISA (1702±268 
and 1268±439, fmol/mL, respectively).
Plasma Ang II and Ang-(1-7) concentrations were addi-
tionally evaluated in the same Ang II postinfusion samples 
using liquid chromatography tandem mass spectrometry.16 
In addition, a major metabolite, the Ang-(1-5), formed from 
Ang-(1-7) was also measured by liquid chromatography 
tandem mass spectrometry (Figure 1). As previously re-
ported,16 noninfused animals had barely detectable levels of 
Ang II (7.5±1.9 fmol/mL), Ang-(1-7; 3.9±0 fmol/mL), and 
Ang-(1-5; 3.0±0 fmol/mL). In Ang II infused mice, Ang II 
and Ang-(1-7) were both markedly elevated (233±20 and 
854±222 fmol/mL, respectively; Figure 1). This is consistent 
with the high levels of these peptides measured by ELISA 
and RIA following Ang II infusion. A high level of Ang-(1-
5), moreover, was also found (233±24 fmol/mL; Figure 1). 
This shows that plasma Ang-(1-7) is formed at a high rate 
when there is a large supply of Ang II and that Ang-(1-7) is 
further degraded to Ang-(1-5).
In Vivo Formation of Ang-(1-7) After Ang II 
Infusion in a Model of Genetic Ablation of ACE2 
and PRCP
We next examined Ang-(1-7) formation in a model of genetic 
ablation of 2 known Ang-(1-7) forming enzymes, ACE2 and 
PRCP. For this, we used a cross of ACE2 KO with PRCP 
KO that we have generated in our laboratory (see section 
Methods). Plasma levels of Ang II at 5 minutes post infu-
sion were high and not significantly different between WT 
and ACE2−/−/PRCP−/− mice (1229±307 and 783±166 fmol/
mL, respectively P=0.3; Figure 2A). Plasma Ang-(1-7) lev-
els also measured 5 minutes after Ang II infusion were mark-
edly elevated and also not significantly different between 
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respectively; P=0.8; Figure 2B). These in vivo findings show 
that Ang-(1-7) formation from Ang II in plasma is essentially 
ACE2- and PRCP-independent.
In Vivo Formation of Ang-(1-7) After Ang II Infusion 
in the Face of Pharmacological POP Inhibition
In these studies, we used ZPP, an inhibitor of POP, given to WT 
and ACE2−/−/PRCP−/− mice infused with Ang II Plasma levels 
of Ang II at 5 minutes post infusion were markedly elevated 
and not significantly different from each other (1651±379 and 
1004±169 fmol/mL respectively; P=0.3; Figure 2A). The ad-
ministration of ZPP largely prevented the elevated Ang-(1-7) 
levels seen at 5 minutes as compared with WT not infused with 
this inhibitor (186±60 and 563±51 fmol/mL, respectively; 
P=0.001; Figure 2B). Similarly, in ACE2−/−/PRCP−/− mice, 
ZPP administration also resulted in markedly lower Ang-(1-7) 
plasma levels as compared with mice without ZPP infusion 
(50±30 and 537±70 fmol/fmol/mL, respectively; P=0.0002; 
Figure 2B). In WT and ACE2−/−/PRCP−/− mice treated with 
ZPP, levels of Ang-(1-7) were reduced and not significantly 
different from each other (P=0.08).
By 30 minutes post-infusion (Figure S3A in the online-
only Data Supplement), the levels of plasma Ang II had mark-
edly decreased in all 4 groups studied. Likewise, the levels 
of plasma Ang-(1-7) had decreased markedly in WT and WT 
treated with ZPP, as well as in ACE2−/−/PRCP−/− The latest 
group had levels of Ang-(1-7) which were barely detectable 
(see Figure S3B).
Plasma Ang II and Ang-(1-7) Levels in WT and 
POP−/− Mice
Baseline Ang II levels in POP−/− mice were higher but not 
significantly different from WT mice (57.8±14 and 31.1±4.4 
fmol/mL, respectively; P=ns; Figure 3A). Plasma Ang-(1-7) 
levels in WT mice were significantly higher than in the POP−/− 
where the levels were not detectable (25.9±11.3 and 0.0 fmol/
mL; P=0.032; Figure 3B).
In Vivo Formation of Ang-(1-7) After Ang II 
Infusion in Mice With Genetic POP Ablation
To confirm the effects of ZPP, we next examined Ang-(1-7) 
formation in POP−/− mice after Ang II infusion using the same 
protocol as in the sections above. In both WT and POP−/− 
mice, plasma Ang II 5 minutes after its infusion was elevated 
and significantly higher in the POP−/− than in the WT mice 
(1120±93 versus 596±234 fmol/mL, respectively P=0.027; 
Figure 3C). This suggests a major role of POP in the degra-
dation of Ang II as in previous protocols the levels of Ang II 
after its infusion were not significantly different than those 
observed in the ACE2−/−/PRCP−/− mice. After Ang II infusion, 
POP−/− mice exhibited lower plasma Ang-(1-7) levels than WT 
mice (309±46 and 472±28 fmol/mL, respectively; P<0.01; 
Figure 3D). Plasma Ang-(1-7) to Ang II ratio after Ang II in-
fusion was also markedly lower in the POP−/− as compared 
with the WT (0.23±0.02 vs 1.53±0.48, respectively; P=0.017). 
These findings show that genetic POP deficiency is associated 
with a significantly reduced ability to convert Ang II to Ang-
(1-7) in plasma in vivo. This results in higher levels of Ang 
II and lower levels of Ang-(1-7) as compared with WT mice.
Blood Pressure Response to Ang II Infusion in 
POP−/− Mice
The effect of Ang II bolus injection (0.2 µg/g BW) on sys-
tolic blood pressure was examined in POP−/− and WT mice 
(n=10 in each group) under light anesthesia. Systolic BP 
peaked in the first minute after Ang II infusion and was not 
significantly different between POP−/− and WT mice (189±5 
versus 186±8 mm Hg; Figure 3E). The recovery from Ang 
Figure 1. Angiotensin peptide levels in serum measured by liquid 
chromatography tandem mass spectrometry (LC/MS-MS) in Ang II 
(Angiotensin II)-infused mice. Plasma showed high levels of Ang II (upper), 
Ang-(1-7) (middle), and Ang-(1-5) (lower) measured by (LC/MS-MS). Blood 
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II-induced acute hypertension was blunted in POP−/− as com-
pared with WT mice (slope 3.06±0.48 versus 4.81±0.45 
mm Hg/minute, respectively; P<0.05). This is consistent 
with higher levels of Ang II and lower levels of Ang-(1-7) 
found in POP−/− mice as compared with WT mice shown in 
(Figure 3C and 3D).
Ex Vivo Formation of Ang-(1-7) From Ang II in 
Kidney and Lung Lysates
Since enzymes residing in highly perfused organs, such as kid-
neys and lungs, might also contribute to circulating Ang-(1-7) 
levels, ex vivo studies on Ang-(1-7) formation from exogenous 
Ang II were performed in lysates from those 2 organs. In WT, 
Figure 2. Ang II (Angiotensin II) and Ang-(1-7) 
levels in plasma measured 5 min post-infusion 
of Ang II. A, Plasma Ang II levels in wild-type 
(WT) and ACE2−/−/PRCP−/− mice were not 
significantly different from each other in the 
absence or with administration of Z-Pro-Prolinal 
(ZPP). B, Ang-(1-7) levels in WT mice with 
ZPP administration (WT+ZPP) were markedly 
reduced as compared with WT without ZPP 
(WT). In the ACE2−/−/PRCP−/− mice, ZPP 
administration also led to much lower Ang 1-7 
levels as compared with ACE2−/−/PRCP−/− mice 
without ZPP (*P<0.05; **P<0.01). In these 
studies, blood was obtained from tail vein at 5 
min and also at 30 min (see online-only Data 
Supplement) after Ang II.
Figure 3. Studies in POPKO mice. A, 
Endogenous Ang II (Angiotensin II) levels in 
plasma of POP−/− mice were higher but not 
significantly different from wild-type (WT) 
controls. B, Endogenous plasma Ang-(1-7) 
levels in POP−/− mice were not detectable 
whereas in WT mice the levels were low, 
but detectable (P=0.032). C, Ang II levels in 
plasma measured 5 min after i.p. injection of 
Ang II were significantly higher in POP−/− mice 
(n=8) than in WT mice (*P<0.05). D, Ang-(1-7) 
levels in plasma also measured 5 min after i.p. 
injection of Ang II were lower in POP−/− mice 
than in WT mice (**P<0.01). Baseline levels 
were measured in blood obtained by cardiac 
puncture while post-Ang II infusion blood 
was obtained by tail snip. E, Systolic blood 
pressure (SBP) after single i.p. bolus injection 
of Ang II (time point 0) under light ketamine 
anesthesia WT and POP−/− mice (n=10 in each 
group). The SBP was recorded every 30 s for 
15 min after Ang II injection. The slope of SBP 
decline was significantly slower in POP−/− than 
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kidneys (n=10) spiked with Ang II, Ang-(1-7) levels peaked 
at 15 minutes (Figure 4) As depicted in one example under 
methods (Figure S2) by 15 minutes, there is a rapid decline 
in Ang II such that by 60 minutes essentially all of the added 
Ang II has dissipated. ZPP had a minimal and not significant 
effect on Ang-(1-7) formation at 15 minutes as compared with 
WT kidneys not incubated with this inhibitor (417±32 versus 
352±75, pmol/mL, respectively; P=0.3). To confirm the lack 
of effect of ZPP in the kidney tissue, we used another inhibitor 
of POP, S-17092.48,49 In WT kidney lysates, the latter inhibitor 
also did not reduce Ang-(1-7) formation significantly (peak at 
15 minutes: 417±32 versus 385±35 pmol/mL; P=ns).
In kidney lysates from ACE2−/−/PRCP−/− mice, the peak 
Ang-(1-7) levels were much lower than in WT (94±18 versus 
417±32 pmol/mL; Figure 4A). Addition of a POP inhibitor, 
ZPP (n=7), reduced Ang-(1-7) to undetectable levels at all 
time points assessed (Figure 4A). In the aggregate, the data 
show that the formation of Ang-(1-7) in mouse kidneys is 
highly dependent on ACE2 and minimally dependent on POP.
In lung lysates from WT mice, the Ang II decline was 
slower than with kidney lysates when equivalent amounts of 
both tissues were exposed to the peptide (Figure S2). The lev-
els of Ang-(1-7) after 15 minutes of incubation with Ang II 
declined at 30 minutes and reached almost undetectable levels 
at 60 minutes of incubation (Figure 4B). Generation of Ang-
(1-7) in lung lysates from ACE2−/−/PRCP−/− mice was not sig-
nificantly different from that of WT lung lysates (peak values 
at 15 minutes, 313±31 versus 230±33 pmol/mL, respectively; 
P=0.09; Figure 4B). Addition of ZPP completely prevented 
Ang-(1-7) formation from Ang II in lung lysates from both 
WT and ACE2−/−/PRCP−/− mice (Figure 4B). Using another 
POP-inhibitor, S-17092, the peak Ang-(1-7) formation at 15 
minutes was also prevented entirely (3±3 versus 182.8±23 
pmol/mL, respectively; Figure S4A). These findings show 
that in mouse lungs, Ang-(1-7) formation from Ang II is es-
sentially ACE2 independent and entirely prevented by POP 
inhibitors. We also measured for comparison the formation 
of Ang-(1-7) from exogenous Ang I in lung tissue (Figure 
S4B). Inhibition of POP with S-17092 significantly, but in-
completely reduced the peak formation of Ang-(1-7). An in-
hibitor of Neprilysin (Thiorphan) also reduced the peak level 
of Ang-(1-7) from Ang I to an extent similar to S-17092. The 
combination of both inhibitors markedly reduced Ang-(1-7) 
formation (Figure S4B).
To further determine the contribution of POP in the for-
mation of Ang-(1-7) from Ang II, we used kidney and lung 
tissues from POP−/− mice and their respective WT counterparts 
(Figure 4C and 4D). In kidneys from WT and POP−/− mice, 
Ang-(1-7) formation from Ang II over time was almost iden-
tical (Figure 4C). The specific ACE2 inhibitor, MLN-4760 
(10−5 M) completely obliterated generation of Ang-(1-7) from 
Ang II (Figure 4C). In contrast to kidney lysates, lung lysates 
from POP−/− mice showed almost undetectable Ang-(1-7) for-
mation from Ang II (Figure 4D). Addition of MLN had no 
effect in the POP−/− lungs. In summary, in kidneys lysates, 
Ang-(1-7) formation is predominantly ACE2-dependent 
whereas in lung lysates the Ang-(1-7) formation from Ang II 
is essentially ACE2-independent and entirely POP dependent.
Ex Vivo Formation of Ang-(1-7) From Ang II in 
Mouse Serum
To determine the contribution of POP to Ang-(1-7) genera-
tion in serum, Ang-(1-7) formation from added Ang II was 
studied ex vivo with (n=6) and without (n=6) addition of ZPP 
(10−5 M; Figure 5A). Incubation of the WT sera with Ang II 
resulted in formation of Ang-(1-7) that peaked at 15 minutes 
and was no longer detectable at 120 minutes of incubation 
(Figure 5A). At 15 minutes, ZPP lowered Ang-(1-7) forma-
tion by 85.8% (4.5±4.5 versus 31.8±6.3 pmol/mL; P=0.01), 
and at 30 minutes by 72% (8.9±4.5 versus 31.8±6.7 pmol/mL; 
P=0.01), respectively.
We next evaluated the contribution of ACE2, PRCP, and 
POP to ex vivo conversion of Ang II to Ang-(1-7) in sera 
obtained from mice deficient in those enzymes. For this, Ang 
Figure 4. Ex vivo Ang-(1-7) formation from Ang 
II (Angiotensin II) in kidney and lung lysates as 
assessed by the peak levels of Ang-(1-7) at 15 
min (see section Methods). Experiments with each 
lysate were performed on 2 different occasions 
in duplicate. A, In wild-type (WT) kidney lysates, 
the POP inhibitor, Z-Pro-Prolinal (ZPP), did not 
affect Ang-(1-7) formation from Ang II significantly 
as compared with WT lysates without ZPP. In 
ACE2−/−/PRCP−/− kidney lysates, Ang-(1-7) was 
markedly decreased. In ACE2−/−/PRCP−/− kidney 
lysates, ZPP addition decreased Ang-(1-7) to 
essentially nondetectable levels. B, In WT lung 
lysates, ZPP completely prevented Ang-(1-7) 
formation from Ang II (compare WT and WT+ZPP). 
In ACE2−/−/PRCP−/− lung lysates, Ang-(1-7) levels 
were not reduced (actually, they were higher) and 
ZPP resulted in undetectable Ang-(1-7) levels. C, 
In POP−/− kidney lysates, Ang-(1-7) formation from 
Ang II was not different from that of WT lysates. 
In contrast, in POP−/− kidney lysates, an addition 
of MLN-4760, a specific inhibitor of ACE2, was 
associated with no detectable Ang-(1-7) formation 
from Ang II. D, In POP−/− lung lysates, Ang-(1-7) 
formation was completely prevented as compared 
with WT lung lysates and addition of MLN-4760 
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II was incubated with sera from the various KO models and the 
resultant formation of Ang-(1-7) was compared. Incubation of 
the sera from ACE2−/−/PRCP−/− mice with Ang II resulted in 
essentially the same formation of Ang-(1-7) as in WT mice 
(Figure 5B). There was no significant difference between WT 
mice (n=6) and ACE2−/−/PRCP−/− (n=3) at 30 minutes (32±6 
versus 17±7 pmol/mL, respectively; P=ns) or at 15 minutes 
(31.8±6.7 versus 17.8±6 pmol/mL, respectively; P=ns), which 
is the peak of Ang 1-7 formation.
In contrast, the amount of Ang-(1-7) formed from Ang 
II by the sera from POP−/− mice was markedly reduced 
compared with both ACE2−/−/PRCP−/− mice and WT mice 
(P<0.01; Figure 5B).
ACE2 and POP Proteins in WT Sera, Lung, and 
Kidneys
By Western blot, ACE2 protein was not detectable either in 
serum or in the lungs but was abundant in kidneys of WT mice 
(Figure 6A). In contrast, POP protein was present in serum, 
lungs, and kidney lysates (Figure 6A).
In Vitro Ang-(1-7) and Phe Formation From Ang II
Conversion of Ang II to Ang-(1-7) is associated with a re-
lease of its carboxyterminal amino acid, Phe, that is directly 
proportional to the amount of the generated Ang-(1-7).50 We 
assessed the reaction by both the formation of Ang-(1-7; 
Figure 6B) and the Phe formation (Figure 6C) after incubating 
Ang II with equivalent amounts of murine recombinant (mr) 
POP and mrACE2 in vitro.
Murine rACE2 formed more Ang-(1-7) than mrPOP 
(5.3±0.4 versus 1.3±0.6 pmol/mL; P<0.001; Figure 6B). In 
agreement with this finding, Phe generation by mrACE2 was 
much higher than that formed by equivalent amount of mrPOP 
(789±29 RFU/ng mrACE2 versus 127±12 RFU/ng mrPOP; 
P<0.001; Figure 6C). These data show that rACE2 is intrinsi-
cally considerably more effective in catalyzing the conversion 
of Ang II to Ang-(1-7) than rPOP.
Discussion
The ACE2/Ang-(1-7) axis of the RAS has received 
increased attention and ACE2 is generally considered the 
main Ang-(1-7) forming enzyme from Ang II. There are 2 
other known angiotensinases, PRCP (prolylcarboxypepti-
dase) and (POP) prolyl endopeptidase, which have not been 
as extensively studied but could be as important as ACE2 in 
the processing of Ang II to Ang-(1-7) in body fluids, certain 
organs, and cell types.10,19,22,23,29–33 In the current study, the 
conversion of Ang II to Ang-(1-7) by these enzymes was 
examined in vivo and ex vivo.
We found similarly high levels of Ang-(1-7) in plasma 
being generated following acute Ang II injections to WT 
mice as in mice with combined genetic ACE2 and PRCP de-
ficiency. By contrast, reduced plasma Ang-(1-7) levels were 
found in mice with genetic POP deficiency infused with Ang 
II. Furthermore, the administration of ZPP, an inhibitor of 
PEP, markedly decreased plasma Ang-(1-7) formation from 
infused Ang II in WT and ACE2−/−/PRCP−/− mice. Our study, 
therefore, has demonstrated that the levels of Ang-(1-7) found 
in the circulation immediately after Ang II infusion are largely 
POP dependent and ACE2 and PRCP independent. It should 
be noted that Ang-(1-7) formation in vivo can originate from 
Ang I cleavage.34 As demonstrated in a study by Yamamoto et 
al,34 the formation of circulatory Ang-(1-7) from infused Ang 
I was entirely Neprilysin dependent. While it is important to 
note the there is direct formation of Ang-(1-7) from Ang I, in 
the present study, we are mainly concerned with the relative 
importance of enzymes that cleave Ang II to form Ang-(1-7).
The physiological importance of POP in terms of systemic 
blood pressure was examined in a model of acute hypertension 
induced by Ang II infusion using the same dosing and timing 
as in the studies examining the conversion of Ang II to Ang-
(1-7). In this model, the blood pressure (BP) response was 
altered in mice with the genetic absence of POP as shown by a 
blunted recovery from Ang II-induced hypertension This can 
be attributed to the diminished Ang II degradation and Ang-
(1-7) formation in the absence of POP. It is not possible to 
precisely discern the contribution of Ang II (pro-hypertensive) 
or Ang-(1-7; antihypertensive) or both on the BP response in 
this model. Of note, in the POP−/− model, the peak level of 
Ang II after its infusion was higher than in WT. By contrast, 
it was not significantly different between WT and ACE2−/−/
PRCP−/− mice. As previous studies have shown no effect or 
only a marginal effect of Ang-(1-7) on BP,15,51 we surmise that 
Figure 5. Ex vivo formation of Ang-(1-7) from Ang II (Angiotensin II) in 
serum. Ex vivo Ang-(1-7) formation after incubation with Ang II in sera from 
(A) wild-type (WT) mice, without Z-Pro-Prolinal (ZPP) and with ZPP and (B) 
serum from from ACE2−/−/PRCP−/− mice and POP−/− mice. A, In wild-type 
(WT) sera (n=6) in the presence of the dual POP (prolyloligopeptidase)/
PRCP (prolylcarboxypeptidase) inhibitor, ZPP (10−5 M), Ang-(1-7) formation 
from Ang II is markedly lower than in the absence of ZPP (P<0.01 by GLM 
statistics over time). B, In sera from POP−/− mice (n=4), Ang-(1-7) formation 
from Ang II is markedly lower than in the sera from ACE2−/−/PRCP−/− mice 
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in this model of acute Ang II-induced hypertension, the slug-
gish recovery observed in POP−/− mice was largely attributable 
to decreased rate of Ang II degradation as compared with the 
WT after Ang II infusion. It should be noted that POP is also 
involved in the metabolism of other vasoactive peptides such 
as bradykinin. Therefore, in our POP−/− model, the changes 
observed in blood pressure response might be influenced by 
RAS independent mechanisms. It should also be acknowl-
edged that the i.p. route gives more time for extravascular 
processing of Ang II to Ang-(1-7) outside the circulation as 
compared with the i.v. route.
To gain further insight into where in the body the con-
version of Ang II to Ang-(1-7) may take place after Ang II 
infusion, we performed ex vivo studies in plasma, lung, and 
kidney lysates. We found that POP protein was present in sub-
stantial amounts in mouse serum by western blot. ACE2, by 
contrast, was scarcely present in serum, which is consistent 
with previous reports.14,15,52,53 In sera from WT mice with the 
POP inhibitor, ZPP, formation of Ang-(1-7) from added Ang 
II, moreover, was markedly diminished. Consistent with this 
finding, a marked attenuation of Ang-(1-7) formation was also 
observed in sera from mice with genetic POP deficiency. The 
presence of POP in plasma and its ability to form Ang-(1-7) 
demonstrated in these studies supports the role of this enzyme 
as a contributor to Ang-(1-7) formation in vivo. This does not 
mean, however, that POP resident in plasma accounts predom-
inantly for the rapid conversion of Ang II to Ang-(1-7). POP 
could originate from the vascular endothelium and there is ev-
idence that endothelial cells in culture have POP.54 In addition, 
circulating cells such as macrophages that are rich in this en-
zyme55 could contribute to the conversion of Ang II to Ang-(1-
7) after Ang II infusion.
Figure 6. ACE2 (angiotensin-converting enzyme 2) and POP proteins in wild-type (WT) sera, lung, and kidneys and the effect of rACE2 and rPOP on Ang-
(1-7) and Phenylalanine formation. A, ACE2 and POP proteins in WT sera, lung, and kidneys by Western blot. ACE2 protein is abundant in kidneys, but not 
in serum or lungs. POP protein is present in serum, lungs, and kidneys. B, In vitro Ang II (Angiotensin II) to Ang-(1-7) conversion assessed by equivalent 
amounts of recombinant (r) ACE2 and rPOP is higher with rACE2 than with rPOP (***P<0.001). C, generation of free Phenylalanine (Phe) from Ang II as a 
substrate by equivalent amounts of recombinant (r) ACE2 and rPOP is higher with rACE2 than with rPOP (***P<0.001). For Western blot, different amounts of 
mouse recombinant protein standards were loaded to estimate ACE2 and POP protein expression levels in sera (1 µL), lung, and kidney lysates (50 µg total 




 http://ahajournals.org by on M
arch 26, 2020
180  Hypertension  January 2020
Another possibility that we think most likely is that POP in 
plasma comes from the lung circulation, similar to circulating 
plasma ACE.56 This issue was partly addressed by examining 
Ang-(1-7) formation from exogenous Ang II in ex vivo stud-
ies using lung lysates. Our ex vivo studies provide compel-
ling evidence for POP as the main Ang-(1-7) forming enzyme 
from Ang II in the lungs whereas ACE2 and PRCP have only 
a marginal if any effect in this organ. According to the Human 
Protein Atlas, ACE2 protein expression was not detectable 
in human pneumocytes or in alveolar macrophages (https://
www.proteinatlas.org/ENSG00000130234-ACE2/tissue). 
ACE2 mRNA expression was also low and mainly localized 
in pneumocytes and endothelial cells. Other studies show also 
low ACE2 mRNA and protein expression in rodent lungs.57,58 
Our results are therefore consistent with these previous studies 
showing low lung ACE2 activity.
In sharp contrast to the lungs, in mouse kidneys, the con-
version of Ang II to Ang-(1-7) was almost entirely ACE2-
dependent. Kidney lysates from ACE2−/−/PRCP−/− showed 
markedly lower Ang-(1-7) generation from Ang II than those 
of WT kidneys. In POP−/− kidney lysates, which exhibited al-
most identical generation of Ang-(1-7) from Ang II as the WT 
kidneys, a specific ACE2 inhibitor (MLN-4760) completely 
abrogated the formation of Ang-(1-7). These ex vivo studies 
overall show that ACE2 is responsible for the formation of 
Ang-(1-7) from Ang II in mouse kidney, which is consistent 
with findings reported for human kidneys.59 In addition, in our 
study, ZPP did not reduce Ang-(1-7) formation from Ang II 
in kidney lysates from WT mice suggesting minimal, if any, 
effect of PRCP on Ang-(1-7) formation from Ang II by the 
kidney at a physiological pH. One cannot exclude, however, 
the possibility that PRCP could play an important role in Ang 
II to Ang-(1-7) conversion in certain regions of the kidney 
where acidic conditions prevail, such as the lumen of the col-
lecting duct. In fact, PRCP is abundant in the kidney collect-
ing tubules, where the prevailing pH is low.20
The relative potency of each of the Ang-(1-7) forming 
enzymes and their kinetic properties need to be taken into con-
sideration together with the relative site abundance of each 
enzyme. About 10× higher catalytic constant for the conver-
sion of Ang II to Ang-(1-7) for ACE2 than POP was previ-
ously reported by Chappell et al.60 Earlier studies by Ward 
et al documented the kinetic parameters of POP-related Ang 





 (1.70±0.09 µmol×minute−1×mg−1) values for 
POP with Ang II as a substrate61 allowed us an approximation 
of POP catalytic efficiency (kcat/Km) to be ≈5× to 10× lower 
than those reported for human ACE2.4,5 Using 2 independent 
methods: Ang-(1-7) formation and Phe generation50 (which is 
a cleavage by-product of Ang II to Ang-(1-7) conversion)50 we 
found, moreover, that ACE2 is much more efficient than POP 
which is consistent with findings of Chappell et al.60 We show 
that both enzymes are present in the kidney by western blot 
but the higher potency of ACE2 confers much greater capacity 
for Ang-(1-7) formation from Ang II in this organ. Moreover, 
one has to take into account the subcellular localization of the 
enzymes. POP is mainly a cytosolic enzyme but also has been 
reported to have membrane-bound isoforms.62,63 As a limita-
tion of this study, we wish to point out that the doses of Ang 
II used to demonstrate Ang-(1-7) generation are high relative 
to the levels of Ang II normally present in plasma. Peptidases, 
however, are most efficient at their Km values and the dose of 
ANG II used in our studies was only twice the Km for POP 
and ACE2. While the balance between these 2 peptidases in 
the metabolism of Ang II that we have demonstrated under 
conditions of high Ang II levels, both in vivo and ex vivo, 
may not mimic the physiological levels of Ang II, the doses 
of this peptide used are appropriate to demonstrate Ang (1-7) 
formation. The fact that in the POP KO the levels of Ang II 
were higher than in the corresponding WT controls supports, 
moreover, the importance of POP in the metabolism of this 
peptide in vivo. In contrast, the baseline levels of Ang II were 
not higher in ACE2 KO mice as compared with wild type.64
Our study did not address the possible function of POP 
within the kidney or the lungs. As the conversion of Ang II to 
Ang-(1-7) within the kidney is largely POP-independent, it is 
possible that this enzyme exerts kidney actions unrelated to 
this conversion. For instance, POP has been reported to foster 
antifibrotic processes in kidney tissue by releasing N-acetyl-
seryl-aspartyl-lysyl-proline (Ac-SDKP) from thymosin-β4.65 
By contrast, POP is the main Ang-(1-7) forming enzyme in 
the lungs and moreover the lung circulation is possibly a major 
source of POP protein for conversion of Ang II to Ang-(1-7) in 
the circulation. Myöhänen et al66 reported that POP can be local-
ized in several human peripheral tissues including kidneys and 
lungs. Further studies ideally using human tissues and human 
plasma are needed to elucidate the physiological function of the 
POP/Ang-(1-7) axis. Our findings show that conversion of Ang 
II to Ang-(1-7) in the circulation and lungs is essentially POP-
dependent and ACE2-independent. In contrast, this reaction in 
the kidney is predominantly mediated by ACE2. These findings 
may have important implications for therapeutic purposes when 
targeting Ang-(1-7) formation from Ang II in the circulation 
and specific organs. Future studies are also needed to fully eval-
uate the kidney and cardiovascular phenotype of POP−/− mice.
Perspectives
There are at least 3 enzymes known to form Ang-(1-7) di-
rectly from AngII, but their relative importance in the circu-
lation and various organs is not known.This is the first study 
to demonstrate that conversion of Ang II to Ang-(1-7) in the 
circulation and lungs is essentially POP-dependent and ACE2-
independent. In contrast, this conversion in the kidney is pre-
dominantly mediated by ACE2. Deficiency of POP by slowing 
down the dissipation of Ang II in the circulation may predispose 
to hypertension. Our findings therefore may have important 
implications for therapeutic purposes when targeting Ang-(1-7) 
formation from Ang II in the circulation and specific organs.
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What Is New?
•	The first study to characterize ACE2 (angiotensin-converting enzyme 
2)- and PRCP (prolylcarboxypeptidase)-independent Ang-(1-7) forma-
tion from Ang II (Angiotensin II) in circulation and peripheral tissues 
using ACE2−/−/PRCP−/− and POP−/− genetic mouse models and pharma-
cological inhibitors.
What Is Relevant?
•	Circulatory and pulmonary Ang-(1-7) formation from exogenous Ang II is 
essentially ACE2 independent and POP dependent while in kidneys the 
conversion is mainly dependent on ACE2.
•	Blood pressure recovery from acute Ang II-induced hypertension is de-
layed in POP-deficient mice.
Summary
This study demonstrates the relevance of the POP/Ang-(1-7) axis in 
the circulation and in the lungs while confirming the importance of 
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